NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Sarcoma Alliance for Research through Collaboration
University Hospital Muenster
Dana-Farber Cancer Institute